Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double Blind, Clinical Trial (RCT) to Assess the Efficacy, Safety, and Tolerability of Oral CBP-0276 200mg QD, 800mg QD or Placebo for CBP-0276, Administered to Adults With Active Psoriatic Arthritis (PsA).

NCT07706530 is registered in ClinicalTrials.gov with Clarent Biopharma, Inc. as lead sponsor.

NCT NCT07706530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07706530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double Blind, Clinical Trial (RCT) to Assess the Efficacy, Safety, and Tolerability of Oral CBP-0276 200mg QD, 800mg QD or Placebo for CBP-0276, Administered to Adults With Active Psoriatic Arthritis (PsA).
Lead sponsor
Clarent Biopharma, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
March 31, 2027
Enrollment
240 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arthritic psoriasis